title: Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.
abstract: The use of prescription medication to augment cognitive or affective function in healthy persons-or neuroenhancement-is increasing in adult and pediatric populations. In children and adolescents, neuroenhancement appears to be increasing in parallel to the rising rates of attention-deficit disorder diagnoses and stimulant medication prescriptions, and the opportunities for medication diversion. Pediatric neuroenhancement remains a particularly unsettled and value-laden practice, often without appropriate goals or justification. Pediatric neuroenhancement presents its own ethical, social, legal, and developmental issues, including the fiduciary responsibility of physicians caring for children, the special integrity of the doctor-child-parent relationship, the vulnerability of children to various forms of coercion, distributive justice in school settings, and the moral obligation of physicians to prevent misuse of medication. Neurodevelopmental issues include the importance of evolving personal authenticity during childhood and adolescence, the emergence of individual decision-making capacities, and the process of developing autonomy. This Ethics, Law, and Humanities Committee position paper, endorsed by the American Academy of Neurology, Child Neurology Society, and American Neurological Association, focuses on various implications of pediatric neuroenhancement and outlines discussion points in responding to neuroenhancement requests from parents or adolescents. Based on currently available data and the balance of ethics issues reviewed in this position paper, neuroenhancement in legally and developmentally nonautonomous children and adolescents without a diagnosis of a neurologic disorder is not justifiable. In nearly autonomous adolescents, the fiduciary obligation of the physician may be weaker, but the prescription of neuroenhancements is inadvisable because of numerous social, developmental, and professional integrity issues.
authors.affiliation: Departments of Pediatrics and Neurology, Yale University, New Haven, CT, USA. william.graf@yale.edu
authors.forename: William D
authors.initials: WD
authors.lastname: Graf
authors.forename: Saskia K
authors.initials: SK
authors.lastname: Nagel
authors.forename: Leon G
authors.initials: LG
authors.lastname: Epstein
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Miller
authors.forename: Ruth
authors.initials: R
authors.lastname: Nass
authors.forename: Dan
authors.initials: D
authors.lastname: Larriviere
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003657:Decision Making / Q000502:physiology; D011307:Drug Prescriptions; D004992:Ethics, Medical; D006801:Humans; D009014:Morals; D010372:Pediatrics
chemical_list: D000697:Central Nervous System Stimulants